In this work, a series of benzylsulfone coumarin derivatives 5a–5o were synthesized and characterized. Kinase inhibitory activity assay indicated that most of the compounds showed considerable activity against PI3K. Anti-tumor activity studies of the active compounds were also carried out in vitro on the Hela, HepG2, H1299, HCT-116, and MCF-7 tumor cell lines by MTS assay. The structure–activity relationships (SARs) of these compounds were analyzed in detail. Compound 5h exhibited the most potent activities against the mentioned cell lines with IC₅₀ values ranging from 18.12 to 32.60 μM, followed by 5m with IC₅₀ values of 29.30–42.14 μM. Furthermore, 5h and 5m clearly retarded the migration of Hela cells in vitro. Next, an in silico molecular docking study was conducted to evaluate the binding models of 5h and 5m towards PI3Kα and PI3Kβ. Collectively, the above findings suggested that compounds 5h and 5m might be promising PI3K inhibitors deserving further investigation for cancer treatment.

In this work, a series of novel benzyl sulfoxide 2-indolinone derivatives was designed and synthesized as potent anticancer agents. Tyrosine kinase inhibitory activity assay indicated that most of the compounds showed significant activity. The in vitro antiproliferative activity of these compounds was further investigated against five human cancer cell lines (HeLa, HepG2, MCF-7, SCC-15, and A549). Several compounds exhibited evident activities. Among them, (Z)-3-(((4-bromobenzyl)sulfinyl)methylene)indolin-2-one (6j) and (Z)-3-((benzylsulfinyl)methylene)-5-bromoindolin-2-one (6o) were found to be effective tyrosine kinase inhibitors (IC₅₀ = 1.34 and 2.69 μM, respectively) in addition to having noteworthy antitumor potential (the average IC₅₀ value of 6j or 6o was less than 40 μM). This class of novel derivatives has promising potential for further development as anticancer agents.

A series of benzofuran derivatives were designed and synthesized, and their inhibitory activites were measured against the SIRT1–3. The enzymatic assay showed that all the compounds showed certain anti-SIRT2 activity and selective over SIRT1 and SIRT3 with IC₅₀ (half maximal inhibitory concentration) values at the micromolar level. The preliminary structure–activity relationships were analyzed and the binding features of compound 7e (IC₅₀ 3.81 µM) was predicted using the CDOCKER program. The results of this research could provide informative guidance for further optimizing benzofuran derivatives as potent SIRT2 inhibitors.

In order to identify promising radioprotector candidates, a series of benzyl sulfoxide/sulfone coumarin derivatives were designed and synthesized based on the reported activity of Ex-Rad. Most of the target compounds demonstrated significant radioprotective effects at concentrations of 40 μmol/L and 20 μmol/L in HUVECs. Among them, compounds 5q and 5u displayed superior activity in mitigating DNA damage compared with Ex-RAD. Notably, compound 5u significantly enhanced the viability of mice exposed to a lethal dose of ionizing radiation. In summary, the above findings suggested that compound 5u might be a promising radioprotective agent deserving further investigation.